Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples